|Bid||4.46 x 1000|
|Ask||4.50 x 900|
|Day's Range||4.4999 - 4.5000|
|52 Week Range||3.7200 - 9.4800|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you want to know who really controls IRIDEX CorporationRead More...
IRIDEX Corporation (IRIX) today announced that it has resolved its differences with Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. (collectively, “Quantel”) in its lawsuit filed against Quantel in the U.S. District Court for the Northern District of California. IRIDEX dismissed the lawsuit it had filed in January 2018, alleging that Quantel products infringed IRIDEX’s U.S. Patent No. 7,771,417, that Quantel breached an earlier agreement between the parties, and that Quantel infringed IRIDEX’s MicroPulse® U.S. Trademark, Registration No. 4550188 on the principal register.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
IRIDEX Corporation (IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018. “Our fourth quarter results completed an exciting year for IRIDEX. Our commercial teams continued to drive growth in Cyclo G6 placements and we shipped a record number of G6 probes in the quarter.
The direct benefit for IRIDEX Corporation (NASDAQ:IRIX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
IRIDEX Corporation (IRIX) today announced Chief Financial Officer Atabak Mokari will leave the Company for a senior finance executive role at another company. Mokari has agreed to assist in the orderly transition of his CFO responsibilities and will leave the Company effective December 18, 2018. IRIDEX plans to search for a replacement.
If you are currently a shareholder in IRIDEX Corporation (NASDAQ:IRIX), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. Read More...
Iridex (IRIX) delivered earnings and revenue surprises of 10.34% and 17.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Mountain View, California-based company said it had a loss of 26 cents. The medical laser company posted revenue of $11.3 million in the period. Iridex expects full-year revenue ...
Anyone researching IRIDEX Corporation (NASDAQ:IRIX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...
The Mountain View, California-based company said it had a loss of 28 cents per share. The medical laser company posted revenue of $10.3 million in the period. Iridex expects full-year revenue in the range ...